Considerazioni sul percorso di sviluppo di un farmaco. II "caso" dello spironolattone

Translated title of the contribution: The "case" of spironolactone

Stefania De Feo, Cristina Opasich, Alberto Volpi, Luigi Tavazzi

Research output: Contribution to journalArticlepeer-review

Abstract

In the progressive understanding of the heart failure syndrome different models have followed. Current pathophysiology model suggests that heart failure is a neurohormonal disorder: an abnormality in cardiac function and a disturbance in myocardial contractile force is the initiating event in heart failure, and the clinical expression and progression of the disease occurs as a result of subsequent extracardiac alterations. Treatment with drugs capable of antagonizing the effects of neuroendocrine activation, such as angiotensin-converting enzyme inhibitors, beta-blockers and antialdosterone agents have induced a significant reduction in morbidity and mortality in heart failure patients. The progressive understanding of the circulating homeostasis mechanisms moved from the systemic to the paracrine aspects of the neurohormonal systems and contributed to the development of new drugs. Moreover, the analysis of a drug's development can be an important step in the medical knowledge advancement. In this sense, aldosterone and spironolactone became an interesting "case", which is analyzed in this paper, going through the steps that have promoted the spironolactone from a weak diuretic to a neurohormonal drug and, finally, to a "central" drug.

Translated title of the contributionThe "case" of spironolactone
Original languageItalian
Pages (from-to)178-186
Number of pages9
JournalItalian Heart Journal Supplement
Volume3
Issue number2
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The "case" of spironolactone'. Together they form a unique fingerprint.

Cite this